Docket
117th Congress · HOUSE BILLBILL

H.R. 153 — Protecting Consumer Access to Generic Drugs Act of 2021

“To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.”

Health
Introduced Jan 4, 2021
Last action Mar 4, 2021
Pipeline · Bill → Law
Step 1
Introduced
Jan 4, 2021
Step 2
Referred
Mar 4, 2021
E&C · Judiciary
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryNo summary available

No CRS summary available for this bill.

Provisions · 6 sectionsIntroduced in House
Timeline · 5 actions
Mar 4, 2021
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Feb 2, 2021
Referred to the Subcommittee on Health.
Jan 4, 2021
Introduced in House
Jan 4, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jan 4, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.